Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 742.2% from a year ago
Cash & equivalents stood at $177.91M at the end of Q1 FY2026, up 742.2% from a year earlier and up 108.3% from the prior quarter. Over 3 fiscal years it compounded at +47.1% a year.
Context
- Cash & equivalents amounted to 85.3% of total assets at the end of Q1 FY2026, up 72.9 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +742.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 85.41M USD
- Year-over-year change
- +157.1%
- 4-year CAGR
- +5.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.41M | +157.1% |
| FY2024 | 2024-12-31 | 33.22M | +24.2% |
| FY2023 | 2023-12-31 | 26.75M | -0.3% |
| FY2022 | 2022-12-31 | 26.83M | -61.7% |
| FY2021 | 2021-12-31 | 70.1M | — |
Cash & Equivalents vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +742.2% is the 2nd highest of 11, against a peer median of +36.9%.
- Cash & equivalents amounts to 85.3% of total assets for LRMR, versus a peer median of 28.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $263.76M USD | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $229.2M USD | +1668.2% | -2.5% | 86.0% | |
| Mar 2026 | $177.91M USD | +742.2% | +47.1% | 85.3% | |
| Mar 2026 | $175.21M USD | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $131.06M USD | +9.7% | -14.7% | 20.3% | |
| Mar 2026 | $97.6M USD | +98.8% | -26.7% | 29.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M USD | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $61.7M USD | -3.8% | -16.1% | 33.6% | |
| Mar 2026 | $32.19M USD | -43.4% | +48.7% | 12.5% | |
ENGNenGene Holdings Inc. | Apr 2026 | $29.83M USD | -48.2% | +442.5% | 9.7% |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
| Peer median (excluding LRMR) | — | +36.9% | -3.9% | 28.9% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70.1M | 26.83M | 26.75M | 33.22M | 85.41M |
| Short-term Investments | 0 | 91.6M | 60.04M | 150.24M | 51.44M |
| Net Receivables | 208K | 0 | 0 | 1.05M | 747K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 279K | 238K | 709K | 517K | 253K |
| Total Current Assets | 72.2M | 120.74M | 90.18M | 195.3M | 142.02M |
| Property, Plant & Equipment (Net) | 4.46M | 3.69M | 3.76M | 3.72M | 2.69M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.34M | 0 | 1.34M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 669K | 1.98M | 659K | 1.2M | 1.13M |
| Total Non-current Assets | 6.46M | 5.67M | 5.76M | 4.92M | 3.82M |
| Total Assets | 78.67M | 126.41M | 95.94M | 200.23M | 145.84M |
| Account Payables | 1.66M | 1.69M | 1.28M | 2.42M | 5.22M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.11M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 54.69M |
| Total Current Liabilities | 8.85M | 10.71M | 9.51M | 24.36M | 64.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.41M | 4.8M | 4.71M | 4.06M | 2.96M |
| Total Liabilities | 14.25M | 15.5M | 14.22M | 28.41M | 67.76M |
| Common Stock | 18K | 43K | 43K | 64K | 83K |
| Retained Earnings | (116.25M) | (151.61M) | (188.55M) | (269.16M) | (434.83M) |
| Accumulated OCI | (0) | (31K) | 81K | 148K | 54K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 64.41M | 110.9M | 81.72M | 171.81M | 78.09M |
| Total Debt | 6M | 5.41M | 5.55M | 5.12M | 4.07M |
| Net Debt | (64.1M) | (21.42M) | (21.2M) | (28.1M) | (81.35M) |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.